- Research article
- Open Access
Virtual screening and experimental validation of novel histone deacetylase inhibitors
BMC Pharmacology and Toxicology volume 17, Article number: 32 (2016)
Histone deacetylases (HDACs) are promising therapeutic targets for the treatment of cancer, diabetes and other human diseases. HDAC inhibitors, as a new class of potential therapeutic agents, have attracted a great deal of interest for both research and clinical applications. Increasing efforts have been focused on the discovery of HDAC inhibitors and some HDAC inhibitors have been approved for use in cancer therapy. However, most HDAC inhibitors, including the clinically approved agents, do not selectively inhibit the deacetylase activity of class I and II HDAC isforms, and many suffer from metabolic instability. This study aims to identify new HDAC inhibitors by using a high-throughput virtual screening approach.
An integration of in silico virtual screening and in vitro experimental validation was used to identify novel HDAC inhibitors from a chemical database.
A virtual screening workflow for HDAC inhibitors were created by integrating ligand- and receptor- based virtual screening methods. Using the virtual screening workflow, 22 hit compounds were selected and further tested via in vitro assays. Enzyme inhibition assays showed that three of the 22 compounds had HDAC inhibitory properties. Among these three compounds, ZINC12555961 significantly inhibited HDAC activity. Further in vitro experiments indicated that ZINC12555961 can selectively inhibit proliferation and promote apoptosis of cancer cells.
In summary, our study presents three new and potent HDAC inhibitors and one of these HDAC inhibitors shows anti-proliferative and apoptosis-inducing activity against various cancer cell lines. These results suggest that the developed virtual screening workflow can provide a useful source of information for the screening and validation of new HDAC inhibitors. The new-found HDAC inhibitors are worthy to further and more comprehensive investigations.
The dynamic post-translational modification of nucleosomal histones plays a critical role in transcriptional regulation. Hyperacetylation of nucleosomal core histones results in transcriptional activation, while their hypoacetylation leads to transcriptional repression. Modifications of nucleosomal histone acetylation and deacetylation affect the chromatin structure and related gene expression, and thus regulate various cellular processes, including DNA synthesis, cell division and differentiation, apoptosis, and others [1, 2]. The level of histone acetylation is determined by histone acetyltransferase (HAT) and histone deacetylase (HDAC) activities [3, 4]. Impaired HDAC activity could interfere with the balance between HATs and HDACs and thus alter the transcriptional status of many genes, in particular those related to disease. Therefore, HDACs have become promising therapeutic targets for the treatment of cancer, diabetes, and other human diseases [5, 6]. HDACs are classified into four classes (Classes I–IV) depending on their sequence identity and domain organization. Classes I (HDACs 1–3 and 8), II (HDACs 4–7, 9, and 10), and IV (HDAC 11) are referred to as classical HDACs and are generally simultaneously targeted by most HDAC inhibitors . Class III HDACs include Sirt1–7; they are nicotinamide (NAD)-dependent and are insensitive to HDAC inhibitors . To date, a number of HDAC inhibitors have been reported and they can be divided into several structural categories: hydroxamic acids, aliphatic acids, benzamides, cyclic peptides and others [9–11]. HDAC inhibitors have emerged as a new class of therapeutic agents and have generated much interest among pharmacologists, and cancer and diabetes researchers [5, 12, 13]. Three HDAC inhibitors, vorinostat (SAHA) , cyclic peptide FK228 (romidepsin) [15, 16] and belinostat , have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous and peripheral T cell lymphoma. However, most HDAC inhibitors, including the clinically approved agents, non-selectively inhibit the deacetylase activity of class I and II HDACs, and many suffer from metabolic instability. These characteristics have been associated with reduced potency and toxic side effects in vivo . Significant efforts are ongoing to address these and other deficiencies of HDAC inhibitors to improve their HDAC inhibitory potential for the treatment of cancer and other diseases [19–21]. In addition, substantial efforts have been made to develop new HDAC inhibitors with potential therapeutic applications . In the present study, we present a hierarchical virtual screening protocol with SYBYL-X2.0  and Gold 5.2  software suites for the identification of compounds as potential HDAC inhibitors. It provides a stable and reliable solution for virtual screening of HDAC inhibitors based on commercial software’s of drug discovery. A pharmacophore model was built and used for virtual screening to identify candidate compounds from the enamine dataset in the ZINC database . Then, the remaining compounds were docked into the active site of HDAC8. Finally, 22 compounds were identified as the final hit compounds. Enzyme inhibition assays with the HDAC inhibitor drug screening kit showed that three of the 22 compounds had HDAC inhibitory properties. Among these three compounds, ZINC12555961 was confirmed to have significant inhibitory activity against HDACs. Further in vitro cell experiments demonstrated that ZINC12555961 can selectively inhibit proliferation and promote apoptosis of cancer cells.
The GALAHAD module in SYBYL-X 2.0 was adopted for ligand-based pharmacophore modeling. Seven hydroxamic acid inhibitors (marked with * in Table 1) with structural diversity were selected as representative compounds. All parameters were set to their default values (such as aligning molecules with pharmacophore features, no molecular template used, etc.) with the exception of 150 generations and a population size of 100. In the virtual screening process performed with the UNITY module in SYBYL-X2.0, at least five out of seven features in the pharmacophore model had to be matched.
GOLD 5.2 was adopted for molecular docking screening. HDAC8 (PDB id: 1 T69) was selected as the docking target. All the water molecules in HDAC8 were removed and hydrogen atoms were added. The binding site of HDAC8 was defined as those residues within 10 Å from the ligand in the X-ray structures. The parameters of the genetic algorithm (GA) were used in default values (such as the population size of 100, the selection pressure of 1.1, etc.) except that ligands were subjected to 30 GA runs, the number of operations was set to 300,000, and the early termination option was turned off. The three top scoring conformations of every ligand were retained at the end of the calculation. Two of the fitness functions implemented in GOLD 5.2, ChemPLP and ChemScore were used in our experiments.
HDAC inhibitory activity assay
The HDAC inhibitor drug screening kit (k340-100, BioVision, CA, USA) was used to measure HDAC inhibitory activities of the candidate compounds according to the manufacturer’s instructions. The candidate compounds, assay buffer, and HDAC fluorometric substrate, which comprises an acetylated lysine side chain, were added to HeLa nuclear extracts in a 96-well plate and incubated at 37 °C for 30 min. The reaction was stopped by adding lysine developer, and the mixture was incubated for another 30 min at 37 °C. An additional positive control included incubation with double-distilled water, and the inhibitor control consisted of incubation with Trichostatin A (TSA) at 20 μM. HDAC activities were quantified by a fluorescence plate reader (POLARstar OPTIMA, BMG, BRD) with excitation at 370 nm and emission at 450 nm.
Four cell lines, namely HepG2 (human hepatocellular carcinoma cell line), L02 (human normal liver cell line), MDA-MB-231 (human breast cancer cell line), and MCF-10A (human normal breast cell line), were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in an appropriate medium supplemented with 10 % fetal bovine serum (TBD Science, Tianjin, China), 100U/ml penicillin and 100 mg/mL streptomycin (Ameresco, US) at 37 °C and 5 % CO2.
The MTT (3-(4, 5-dimethylthia-zol-2-yl)-2, 5-diphenyl tetrazolium bromide) assay was used to examine the effects of the candidate compounds on cell viability. The candidate compounds were dissolved in DMSO (dimethyl sulfoxide) as 10 mM/L stock solutions. Cells were plated in 96-well plates (1 × 104 cells/well) in 100 μL of growth medium and allowed to grow for 24 h. The cells were then treated with 0, 1, 10, 50 and 100 μM of each candidate compound in the presence of 3 % serum. After 44 h of treatment, 20 μL of MTT [5 mg/mL in phosphate-buffered saline (PBS); Sigma Chemical Co.] were added to each well for an additional 4 h of incubation. The blue MTT formazan precipitate was dissolved in 100 μL of DMSO. The optical density of samples was measured at 570 nm using a micro ELISA reader (Bio-Rad, Hercules, CA). Cell viability was expressed as a percentage relative to the untreated control cells.
DAPI staining assay
A DAPI staining assay was performed to reveal the presence of condensing nuclei and apoptotic bodies in compound-treated cells. HepG2 and MDA-MB-231 cells were treated with the candidate compounds (60 and 90 μM) for 48 h, and then harvested, fixed with 4 % paraformaldehyde for 30 min, washed with PBS, and stained with DAPI at a final concentration of 0.5 μg/mL for 15 min at room temperature. The cells were then analyzed using a fluorescence microscope. Three independent experiments were performed, and at least four different fields with a minimum of 100 cells/field were scored.
Annexin V-FITC/PI (propidium iodide) assay was performed to evaluate apoptosis of cancer cells induced by the hit compound ZINC12555961. HepG2 and MDA-MB-231 cells were seeded on 6-well plates at a density of 1 × 106 cells/well, and incubated with 90 μM of ZINC12555961 for 48 h. Then, the cells were harvested by trypsinization, washed in ice-cold PBS, and resuspended in 190 μL binding buffer containing 5 μL Annexin V and 10 μL PI (Beyotime, China). The cells were incubated in the dark for 10 min and then analyzed by flow cytometry (BD FACSCanto™).
Cell cycle analysis
DNA staining with PI (Beyotime, China) was used to determine the cell cycle distribution of compound-treated cells. The number of cells at specific phases of the cell cycle was analyzed and sorted using flow cytometry. HepG2 and MDA-MB-231 cells were seeded at a density of 1 × 106 cells/well. After treatment, the cells were collected, washed with PBS, fixed with 50 % alcohol and stained with PI at a final concentration of 1 mg/mL for 30 min. The percentages of cells in different phases of the cell cycle were measured with a flow cytometer (BD FACSCantoTM) and analyzed with the Modfit software (Verity Software House, Topsham, USA).
Pharmacophore-based virtual screening
The Enamine dataset in the ZINC database, containing collection of 1.8 million structurally diverse compounds, were used as the screening compound set . As listed in Table 1, seven compounds were used to generate pharmacophore models. 50 hydroxamic acid-based HDAC inhibitors collected from the literature [26–31] and Enamine_p0.18, a subset of the enamine dataset , which contains 22,565 compounds, were combined as the test dataset. Moreover, the maximal unbiased benchmarking data sets for HDACs (MUBD-HDACs) that cover all classical HDACs, composed of 631 HDAC inhibitors and 24,609 unbiased decoys , were further used to validate our pharmacophore models. The HDAC inhibitor data sets in MUBD-HDACs have been validated extensively as chemically diverse, while the decoy sets are shown to be property-matching with ligands but have no HDAC inhibitory activities. MUBD-HDACs is freely available at http://www.xswlab.org/. All compounds were minimized under the Tripos Standard (TS) force field with Gasteiger-Hückel atomic partial charges. Minimizations were done using the Powell method and terminated at an energy gradient value of 0.01 kcal/mol. All models derived from at least six ligands of the training set (N_NITS ≥ 6) are listed in Table 2, except those models with high energies. Constructing a good pharmacophore model requires balancing among various criteria such as maximizing steric consensus (STERICS), maximizing the pharmacophore consensus (HBOND), and minimizing strain energy (ENERGY) . SPECIFICITY is a logarithmic indicator of the expected discrimination for each model. It is based on the number of features contained, their distribution across any partial match constraints, and the degree to which the features are separated in space. A good pharmacophore model usually has a higher SPECIFICITY value, a higher steric score and a lower energy value. MODEL_001, MODEL_002, MODEL_005, MODEL_006, MODEL_010, MODEL_021, MODEL_030, and MODEL_041 were selected to further validate their screening abilities for the test dataset and the decoy dataset. The enrichment factor (EF) was calculated using equation (1):
Where D indicates the total number of compounds in the test datasets; A means the total number of known inhibitors in the test datasets; Ht is the hit number of compounds retrieved from the test datasets; and Ha represents the number of known inhibitors in the hit compounds.
As listed in Table 3, the calculation results indicated that MODEL_006 had the best EF values. Moreover, MODEL_006 had the highest SPECIFICITY value, a moderate steric score, and an acceptable energy value. Therefore, it was selected as the final pharmacophore model. As shown in Fig. 1, MODEL_006 included seven pharmacophore features as follows: three hydrophobes (HY5, HY6 and HY7), two hydrogen bond (HB) acceptors (AA3 and AA4), and two HB donors (DA1 and DA2). Note that the pharmacophore AA_4 and DA_2 were overlapped each other. The hydrophobic moieties of the pharmacophore reflect the need for a hydrophobic region such as the linker domain or the cap group domain . The HB acceptor and donor moieties of the pharmacophore reflect the need for the ZBG domain . As a result, MODEL_006 was used as a 3D query to screen the Enamine database using the UNITY search module in SYBYL-X 2.0. In the seven features of MODEL_006, the maximum omitted features were set to two. The final 11,905 hits were retrieved.
Molecular docking-based virtual screening
Initial validation of the docking protocol was performed by re-docking the ligand extracted from the HDAC 8 crystal structure (PDB id: 1 T64) to HDAC 8 itself. The top conformation of the ligand produced by GOLD 5.2 was very close to the crystal structure-bound conformation of the ligand. The root-mean-square deviation between the docked pose and its bound pose in the crystal structure was 0.75 Å. This indicated that GOLD 5.2 is able to reproduce the correct binding pose of an HDAC inhibitor ligand to its receptor. Next, the decoy dataset MUBD-HDACs  were further used to validate our docking protocol. 1 T64, 1 T67 and 1 T69 were used as the receptor protein and the four docking functions in GOLD 5.2 (ChemPLP, Goldscore, Chemscore and ASP) were used as scoring functions. The EF values and functional thresholds of ChemPLP, Goldscore, Chemscore and ASP for the top 1, 5, 10 and 20 % of ranked compounds in the decoy database were listed in Table 4. From the Table 4, we can see that the EF values of ChemPLP and Chemscore are obviously higher than that of Goldscore and ASP. The previous literature also pointed out that ChemPLP demonstrated the best results for both pose prediction and virtual screening . So we chose ChemPLP and Chemscore together to further evaluate their screening results. As listed in Table 5, the combination of the two scoring functions is better in screening results than the two separate functions. Finally, ChemPLP was chosen as the main function and Chemscore was chosen as as the secondary scoring function for practical screening. After validation of the docking protocol, all 11,905 hits retrieved by pharmacophore model-based screening were docked into the active site of three crystal structures of HDAC8 (1 T64, 1 T67 and 1 T69). According to the actual situation, the about top 1 % of ranked compounds in the hit database were decided to remain for experimental validation. The score 72 for ChemPLP and 23 for ChemScore were selected as the final score thresholds. As a results, 154 compounds were selected as the hit compounds. Finally, the Selector module in SYBYL-X 2.0 was adopted for the clustering analysis by creating and comparing diverse subsets of the 154 hit compounds. 22 of the 154 hit compounds with diverse structures were selected as the final hits (listed in Table 6). We further examined the binding patterns of the 22 final hits (Additional file 1: Figure S1). As listed in Table 7, the binding patterns of the 22 hit compounds can be divided into five types. For the first class of compounds, their ZBG domain may form covalent metal chelate complexes and hydrogen bond interactions with HDAC residues. For the second class of compounds, their ZBG domain and the linker domain may form covalent metal chelate complexes and hydrogen bond interactions with HDAC residues. For the third class of compounds, its ZBG domain and cap group domain may form covalent metal chelate complexes and hydrogen bond interactions with HDAC residues GLY151 and TYR306. The fourth class of compounds included ZINC03260906 and ZINC09715944. The ZBG domain of ZINC03260906 may form covalent metal chelate complexes and its linker domain and the cap group domain may form hydrogen bond interactions with HDAC residues HIS180 and PHE208. The ZBG domain of ZINC09715944 may form covalent metal chelate complexes and its linker domain and the cap group domain may form hydrogen bond interactions with HDAC residues LYS33, HIS143, and SER150. The fifth class of compounds included ZINC02627831 and ZINC12581173. The linker domain of ZINC02627831 may form hydrogen bond interactions with HDAC residue ASP101. The ZBG domain of ZINC12581173 may form hydrogen bond interactions with HDAC residue LYS33.
Inhibitory enzymatic activity evaluation
Based on the in silico results, additional in vitro studies were performed to evaluate the activity of the final 22 hit compounds. A fluorometric HDAC activity assay was firstly performed to examine the inhibitory activity of the 22 hit compounds against HDACs in HeLa nuclear extracts (Biovision K340-100). The experimental results are depicted in Fig. 2, which shows that three compounds, namely ZINC12555961, ZINC02639234, and ZINC09715944, inhibited the enzymatic activity of HDACs. Their relative enzymatic activities were 52 % (P = 0.008), 76 % (P = 0.006) and 82 % (P = 0.011), respectively, whereas that of the control inhibitor TSA was 12 % (P = 0.0003). The other 19 hit compounds did not show significant inhibitory activity against HDACs.
The three active compounds did not belong to either of the four main classes of HDAC inhibitors, namely hydroxamic acids, aliphatic acids, benzamides, and cyclic peptides [9–11]. ZINC12555961 has four main functional groups: fluorophenyl, methoxyphenyl, acrylamide cyanide and nitrophenyl; ZINC02639234 has three main functional groups: benzothiazole, triazole and dihydroxy phenyl; and ZINC09715944 has three main functional groups: benzene and pyridazine ketone, pyrrole and methoxypheny. The docking poses of the three active compounds to the active site of HDAC8 (1 T69) are shown in Fig. 3. The two hydroxyls of the dihydroxy phenyl group of ZINC02639234 formed covalent chelate complexes with zinc ions and hydrogen bond interactions with HDAC residues ASP178 and ASP267. In addition, the benzothiazole group of ZINC02639234 had hydrophobic contact with HDAC residue PHE208 (Fig. 3a). For ZINC09715944, its methoxyphenyl group formed covalent chelate complexes with zinc ions, the carbonyl of its linker domain formed hydrogen bond interactions with HDAC residue LYS33, and the carbonyl of its benzene and pyridazine ketone group was not only able to form hydrogen bond interactions with HDAC residues HIS143 and SER150, but was also able to form hydrophobic contact with HDAC residue PHE208 (Fig. 3b). For ZINC12555961, the hydroxyl of its nitrophenyl group was not only able to form covalent chelate complexes with zinc ions, but was also able to form hydrogen bond interactions with HDAC residue ASP267; the nitro of its nitrophenyl group could form hydrogen bond interactions with HDAC residues GLY304, GLN263, GLY140 and HIS142; the carbonyl group of its acrylamide cyanide was able to form hydrogen bond interactions with HDAC residue HIS180, and its methoxyphenyl group was in hydrophobic contact with HDAC residue PHE208 (Fig. 3c). The three compounds were selected for further cytotoxicity assays.
Anti-proliferative activity and apoptosis-inducing mechanism
HDAC inhibitors selectively induce cell growth arrest and apoptosis in a wide variety of cancer cells. To test the cytotoxicity of the three hit compounds with HDAC inhibitory activities, MTT, DAPI staining, and Annexin V-FITC assays were designed and performed according to the procedures described in the Materials and methods section. In the MTT assay, HepG2, L02, MDA-MB-231, and MCF-10A cells were cultured in 3 % serum-supplemented medium and treated with four different concentrations (1, 10, 50, and 100 μM) of the three hit compounds and SAHA. The viabilities of the four cell lines after 48 h of treatment were measured using the MTT assay. The IC50 values for ZINC12555961, ZINC02639234, ZINC09715944 and SAHA against the four cell lines were calculated and are listed in Table 8, which shows that ZINC02639234 and ZINC09715944 exhibited stronger toxicity towards normal cells than against cancer cells, whereas ZINC12555961 showed stronger toxicity towards cancer cells than normal cells. Increasing ZINC12555961 concentrations (from 0 to 100 μM) led to a steady decrease in the viability of MDA-MB-231cells (IC50 = 57 μM), but had a less toxic effect on MCF-10A cells (IC50 = 142 μM). In the HepG2 and L02 cell lines, ZINC12555961 exhibited nearly the same toxicity, with IC50 values of 87 and 85 μM, respectively. Furthermore, in our experiments, ZINC12555961 was more potent than SAHA in inhibiting the viability of cancer cells (Fig. 4). The IC50 values of SAHA in HepG2, L02, MDA-MB-231, and MCF-10A cells were 166 μM, 85 μM, 178 μM, and 59 μM, respectively. The results indicated that ZINC12555961 has inhibitory activity against all four cells and displays promising and selective inhibitory activity against cancer cell viability, ZINC09715944 has inhibitory activity against HepG2, L02, and MCF-10A cells but not against MDA-MB-231 cell and does not display selective inhibitory activity against cancer cell viability, and zinc02639234 has no inhibitory activity against all four cells.
As ZINC12555961 could remarkably suppress the viability of HepG2 and MDA-MB-231 cells, a DAPI staining assay was performed to determine whether its inhibitory effect on cell viability is associated with the induction of cell apoptosis. Fluorescent microscopic images of DAPI stained nuclei of HepG2 and MDA-MB-231 cells treated with ZINC12555961 or DMSO for 48 h are shown in Fig. 5. The concentrations of zinc12555961 used in HepG2 and MD-231 cells were 90 μM and 60 μM, respectively. Apoptotic nuclei in both cell lines were split into several nuclear apoptotic bodies, and apoptotic cells are shown in deep white by DAPI staining, as indicated by the red arrows (Fig. 5b and d), whereas cells treated with DMSO exhibited round intact nuclei. These results indicate that ZINC12555961 may play an important role in inducing cancer cell apoptosis.
Flow cytometric analysis with Annexin V-FITC conjugated to PI was performed to further examine the effect of ZINC12555961 on cancer cell apoptosis. HepG2 and MDA-MB-231 cells were treated with DMSO (90 μM) or ZINC12555961 (90 μM) for 48 h. Apoptotic cells were stained and monitored by flow cytometry (Fig. 6). In both HepG2 and MDA-MB-231 cell lines, ZINC12555961 significantly induced the late apoptotic stage. The apoptosis rates of HepG2 cells treated with DMSO and ZINC12555961 were 5.1 and 47.9 %, respectively, and those of MDA-MB-231 cells treated with DMSO and ZINC12555961 were 6.4 and 25.2 %, respectively. ZINC12555961 also affected the early apoptotic stage in both cell lines. The early apoptosis rates of the control group vs. the experimental group in HepG2 and MDA-MB-231 cells were 3.5 % vs. 4.5 % and 3.9 % vs. 8.7 %, respectively. These results indicate that the rates of apoptosis induced by ZINC12555961 were significantly higher than those of the control groups. ZINC12555961 may play an important role in inducing cancer cell apoptosis.
As shown above, the effects of ZINC12555961 on apoptosis, as measured by flow cytometry, do not explain the decrease of cell viability measured by MTT assay. This suggests that ZINC12555961 may affect cell viability through other mechanisms. Therefore, we tested the effect of ZINC12555961 on cell cycle distribution by flow cytometric analysis. HepG2 and MDA-MB-231 cells were treated with ZINC12555961 for 32 and 48 h and analyzed by flow cytometry (Fig. 7). In the HepG2 cell line, the percentage of cells in the G1 phase decreased from 70.3 to 66.4 % in response to ZINC12555961, and this decrease was accompanied by an increase in the proportion of cells in the G2 phase from 3.5 to 8.3 % (Fig. 7a). Similarly, in MDA-MB-231 cells, the percentage of cells in the G1 phase decreased from 61.5 to 51.6 % in response to ZINC12555961, and this decrease was accompanied by an increase in the proportion of cells in the G2 phase from 12.3 to 24.9 % (Fig. 7b). This indicates that the inhibitory effect of ZINC12555961 on the proliferation of HepG2 and MDA-MB-231 cells may be associated with G2/M phase cell cycle arrest.
HDAC enzymes have emerged as exciting and promising novel targets for the treatment of cancer, diabetes and other human diseases. HDAC inhibitors, as a new class of potential therapeutic agents, have attracted a great deal of interest both for research and clinical applications. Computer aided drug design (CADD) and virtual screening have been applied in the development of new HDAC inhibitors. Many HDAC inhibitors were designed and synthesized based on CADD approaches [35–41]. Certain potent HDAC inhibitors with novel structures were identified by virtual screening approaches [31, 42, 43]. Vadivelan et al. developed a pharmacophore model based on common chemical features of HDAC inhibitors . Melagrakia et al. developed a linear five-parameter quantitative structure-activity relationship (QSAR) model of HDAC inhibitors . Xiang et al. developed a pharmacophore model and three QSAR models for a series of benzimidazole and imidazole inhibitors of HDAC2 . Zhao et al. used a two-step modeling approach to study the selectivity and activity of HDAC inhibitors . Thangapandian et al. used pharmacophore modeling and molecular docking approaches for the identification of potential HDAC8 inhibitors . More recently, Thangapandian et al. used a combined pharmacophore modeling, molecular docking and molecular dynamics (MD) simulation approach for the identification of potential HDAC8 inhibitors . Nair et al. used a combined pharmacophore modeling, flexible docking, and three-dimensional QSAR (3D–QSAR) approach for the identification of benzimidazole and imidazole derivatives . Although these studies did not experimentally validate the activities of their candidate compounds, their use of virtual screening approaches for HDAC inhibitors provides support for further computational and experimental research. Park et al. identified novel classes of HDAC inhibitors with new zinc-chelating groups using docking simulations, and experimentally validated the activities of their candidate compounds . Tang et al. identified three hit compounds using a combinatorial QSAR screening model based on support vector machine and k-Nearest Neighbors algorithms, and experimentally confirmed the inhibitory activities of the compounds against HDAC1 . Zhang et al. identified a potent HDAC inhibitor with a novel scaffold using ZBG (zinc-binding group)-based virtual screening, and experimentally confirmed the inhibitory activities of the compounds against HDAC8 . In the present study, we developed a hierarchical virtual screening protocol for the identification of potential HDAC inhibitor compounds. The multistage virtual screening workflow was used to screen and identify 22 final hit compounds, and the HDAC inhibitory activities of three of the 22 compounds, namely ZINC12555961, ZINC02639234 and ZINC09715944, were experimentally validated by in vitro enzyme inhibition assays. The results confirmed the efficacy and validity of our screening method. The three active compounds showed a novel structure that does not belong to the previously reported four classes of HDAC inhibitors. All three active hits showed different scaffolds, thereby providing wide opportunities for future HDAC inhibitor design. The novelty of the 22 final hit compounds was assessed using SciFinder scholar (https://scifinder.cas.org/). The SciFinder results confirmed that these compounds were not previously tested for HDAC inhibitory activity.
We further examined the cytotoxicity of the three hit compounds with HDAC inhibitory activities against the human normal liver cell line, L02, and the liver cancer cell line, HepG2, as well as the human breast cancer cell line, MDA-MB-231, and the human breast epithelial cell line, MCF-10A. The MTT assay results demonstrated that the active compound ZINC12555961 could selectively suppress the viability of human cancer cell lines (HepG2 and MDA-MB-231 cells). Staining with DAPI and Annexin V-FITC/PI flow cytometry assays revealed that the effect of ZINC12555961 on cancer cell death may be mediated by the induction of apoptosis and G2/M phase cell cycle arrest. These results indicate that ZINC12555961 is a promising HDAC inhibitor and has anti-tumor potential. Future studies will be aimed at elucidating the molecular mechanisms underlying ZINC12555961-induced selective cancer cell apoptosis and evaluating the isoform-selective HDAC inhibitory effects of ZINC12555961. ZINC12555961-focused virtual screening will also be further developed in the future.
In conclusion, the study identified three new HDAC inhibitors. The new-found HDAC inhibitors are worthy to further investigations.
AA, Hydrogen bond acceptors; CADD, Computer aided drug design; DMSO, Dimethyl sulfoxide; EF, Enrichment factor; ELISA, Enzyme-linked immunosorbnent assay; FITC, Fluorescin isothiocyanate; GA, Genetic algorithm; HB, Hydrogen bond donors; HB, Hydrogen bond; HDAC, Histone deacetylases; HepG2, Human hepatocellular carcinoma cell line; HY, Hydrophobes; L02, Human normal liver cell line; MCF-10A, Human normal breast cell line; MDA-MB-231, Human breast cancer cell line; MTT, 3-(4, 5-dimethylthia-zol-2-yl)-2, 5-diphenyl tetrazolium bromide; PBS, Phosphate-buffered saline; PDB, Protein data bank; PI, Propidium iodide; SAHA, Suberoylanilide hydroxamic acid; TSA, Trichostatin A; ZBG, Zinc-binding group
Hassig CA, Schreiber SL. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol. 1997;1(3):300–8.
Moggs JG, Goodman JI, Trosko JE, Roberts RA. Epigenetics and cancer: implications for drug discovery and safety assessment. Toxicol Appl Pharmacol. 2004;196(3):422–30.
Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev. 1999;9(1):40–8.
Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 1998;12(5):599–606.
Christensen DP, Dahllof M, Lundh M, Rasmussen DN, Nielsen MD, Billestrup N, Grunnet LG, Mandrup-Poulsen T. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol Med. 2011;17(5–6):378–90.
Mork CN, Faller DV, Spanjaard RA. A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors. Curr Pharm Des. 2005;11(9):1091–104.
Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004;338(1):17–31.
Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pillus L, Sternglanz R. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci U S A. 2000;97(11):5807–11.
Abend A, Kehat I. Histone deacetylases as therapeutic targets--from cancer to cardiac disease. Pharmacol Ther. 2015;147:55-62.
Rodriquez M, Aquino M, Bruno I, De Martino G, Taddei M, Gomez-Paloma L. Chemistry and biology of chromatin remodeling agents: state of art and future perspectives of HDAC inhibitors. Curr Med Chem. 2006;13(10):1119–39.
Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769–84.
Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002;1(4):287–99.
Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol. 2001;13(6):477–83.
Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discov. 2007;6(1):21–2.
Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827–34.
Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW, Gardner ER, Figg WD, Bates SE. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther. 2010;10(7):997–1008.
Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13(9):673–91.
Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem. 2012;4(4):505–24.
Mendivil AA, Micha JP, Brown 3rd JV, Rettenmaier MA, Abaid LN, Lopez KL, Goldstein BH. Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer. Int J Gynecol Cancer. 2013;23(3):533–9.
Dizon DS, Damstrup L, Finkler NJ, Lassen U, Celano P, Glasspool R, Crowley E, Lichenstein HS, Knoblach P, Penson RT. Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. Int J Gynecol Cancer. 2012;22(6):979–86.
Dizon DS, Blessing JA, Penson RT, Drake RD, Walker JL, Johnston CM, Disilvestro PA, Fader AN. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;125(2):367–71.
McLaughlin F, La Thangue NB. Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol. 2004;68(6):1139–44.
Enamine dataset in the ZINC database. http://zincdockingorg/catalogs/enamine, (accessed 13 June 2014).
Lavoie R, Bouchain G, Frechette S, Woo SH, Abou-Khalil E, Leit S, Fournel M, Yan PT, Trachy-Bourget MC, Beaulieu C, et al. Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg Med Chem Lett. 2001;11(21):2847–50.
Woo SH, Frechette S, Abou Khalil E, Bouchain G, Vaisburg A, Bernstein N, Moradei O, Leit S, Allan M, Fournel M, et al. Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. J Med Chem. 2002;45(13):2877–85.
Estiu G, Greenberg E, Harrison CB, Kwiatkowski NP, Mazitschek R, Bradner JE, Wiest O. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J Med Chem. 2008;51(10):2898–906.
Kozikowski AP, Tapadar S, Luchini DN, Kim KH, Billadeau DD. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J Med Chem. 2008;51(15):4370–3.
Chen Y, Li H, Tang W, Zhu C, Jiang Y, Zou J, Yu Q, You Q. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009;44(7):2868–76.
Tang H, Wang XS, Huang XP, Roth BL, Butler KV, Kozikowski AP, Jung M, Tropsha A. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation. J Chem Inf Model. 2009;49(2):461–76.
Xia J, Tilahun EL, Kebede EH, Reid TE, Zhang L, Wang XS. Comparative modeling and benchmarking data sets for human histone deacetylases and sirtuin families. J Chem Inf Model. 2015;55(2):374–88.
Caballero J. 3D-QSAR (CoMFA and CoMSIA) and pharmacophore (GALAHAD) studies on the differential inhibition of aldose reductase by flavonoid compounds. J Mol Graph Model. 2010;29(3):363–71.
Liebeschuetz JW, Cole JC, Korb O. Pose prediction and virtual screening performance of GOLD scoring functions in a standardized test. J Comput Aided Mol Des. 2012;26(6):737–48.
Guan P, Sun F, Hou X, Wang F, Yi F, Xu W, Fang H. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors. Bioorg Med Chem. 2012;20(12):3865–72.
Zhang L, Wang X, Li X, Xu W. Discovery of a series of small molecules as potent histone deacetylase inhibitors. J Enzyme Inhib Med Chem. 2014;29(3):333–7.
Wang S, Li X, Wei Y, Xiu Z, Nishino N. Discovery of potent HDAC inhibitors based on chlamydocin with inhibitory effects on cell migration. ChemMedChem. 2014;9(3):627–37.
Price S, Bordogna W, Bull RJ, Clark DE, Crackett PH, Dyke HJ, Gill M, Harris NV, Gorski J, Lloyd J, et al. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett. 2007;17(2):370–5.
Guan P, Wang L, Hou X, Wan Y, Xu W, Tang W, Fang H. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif. Bioorg Med Chem. 2014;22(21):5766–75.
Moradei OM, Mallais TC, Frechette S, Paquin I, Tessier PE, Leit SM, Fournel M, Bonfils C, Trachy-Bourget MC, Liu J, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007;50(23):5543–6.
Shultz MD, Cao X, Chen CH, Cho YS, Davis NR, Eckman J, Fan J, Fekete A, Firestone B, Flynn J, et al. Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. J Med Chem. 2011;54(13):4752–72.
Park H, Kim S, Kim YE, Lim SJ. A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups. ChemMedChem. 2010;5(4):591–7.
Zhang L, Li M, Feng J, Fang H, Xu W. Discovery of a novel histone deacetylase 8 inhibitor by virtual screening. Med Chem Res. 2012;21:152–6.
Vadivelan S, Sinha BN, Rambabu G, Boppana K, Jagarlapudi SA. Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads. J Mol Graph Model. 2008;26(6):935–46.
Melagraki G, Afantitis A, Sarimveis H, Koutentis PA, Kollias G, Igglessi-Markopoulou O. Predictive QSAR workflow for the in silico identification and screening of novel HDAC inhibitors. Mol Divers. 2009;13(3):301–11.
Xiang Y, Hou Z, Zhang Z. Pharmacophore and QSAR studies to design novel histone deacetylase 2 inhibitors. Chem Biol Drug Des. 2012;79(5):760–70.
Zhao L, Xiang Y, Song J, Zhang Z. A novel two-step QSAR modeling work flow to predict selectivity and activity of HDAC inhibitors. Bioorg Med Chem Lett. 2013;23(4):929–33.
Thangapandian S, John S, Sakkiah S, Lee KW. Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery. J Mol Graph Model. 2010;29(3):382–95.
Thangapandian S, John S, Lee Y, Kim S, Lee KW. Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery. Int J Mol Sci. 2011;12(12):9440–62.
Nair SB, Teli MK, Pradeep H, Rajanikant GK. Computational identification of novel histone deacetylase inhibitors by docking based QSAR. Comput Biol Med. 2012;42(6):697–705.
This work was supported by the National Natural Science Foundation of China (no. 61172183), the Natural Science Foundation of Jilin Province, China (no. 20130101148JC), the Changchun Science and Technology Bureau, China (no. 12ZX55), Science and Technology Development Program of Jilin Province (No. 20150309003YY), Key Science and Technology Project of Jilin Province (20150224038YY), the 2014 Industrial Technology Research and Development Special Project of Jilin Province, China (no. 2014Y100), and the 2015 Department of Education 12th Five-Year Science and Technology Research Planning Projects of Jilin Province, China (no. 2014B053).
Availability of data and materials
Data used in this study are given as tables and additional files. Details of materials used are available in the reference list.
YXH and YXL conceived and designed the research. JZ, QHS, LHZ, CF and TTL performed the research including data collection, experiments and analysis. YLB, LGS and LBZ suggested extension and modifications to the research. YXH supervised the whole research and revised the manuscript critically. All authors have read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Huang, Yx., Zhao, J., Song, Qh. et al. Virtual screening and experimental validation of novel histone deacetylase inhibitors. BMC Pharmacol Toxicol 17, 32 (2016). https://doi.org/10.1186/s40360-016-0075-8
- HDAC inhibitors
- Virtual screening